Synthesis, Crystal Structure and Bioactivity of Ethyl 1-((2-Brom ophenyl)carbamoyl)-2-(3,4,5-trimethoxyphenyl)cyclopropanecarboxylate
Many small-molecule compounds were reported as microtubule-inhibitor with potential anticancer activities, such as combretastatin-A4 (CA-4) analogue. The title compound which is one novel cyclopropylamide analogue of CA-4, namely as ethyl 1-42-bromophenyl)carbamoyl)-2-(3,4,5-trimethoxyphenyl)cyclopropanecarboxylate, has been synthesized and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to monoclinic, space group P2(1)/n with a = 8.8002(6), b = 11.4525(8), c = 21.7870(16) angstrom, beta = 93.810(3)degrees, V = 2190.9(3) angstrom(3), Z = 4, C22H23BrNO6, M-r = 477.32, D-c = 1.447 Mg/cm(3), F(000) = 980, lambda(CuK alpha) = 1.54178 angstrom, mu = 2.883 mm (-1), R= 0.0691 and wR= 0.1958 for 6420 observed reflections (I> 2 sigma(I)). Importantly, the compound revealed potential anticancer activities in six cancer cells and could stimulate tubulin polymerization in vitro, indicating that the small-molecule could be selected as a lead compound for the development of microtubule stimulator.